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increased to 42.6% by 2005. In 2000, 89.5% of all AMI
patients was treated with thrombolysis as primary intervention,
7.8% underwent PCI, and 2.6% CABG; by 2005 these percent-
ages changed to 21.1%, 73.1%, and 5.8% respectively. We
compared the 30-day and one year mortality by intervention
groups. In 2005 without any intervention it was 27.5% vs
37.8% (30 days and 1 year), in the PCI group 6.1% vs 9.7%,
in the thrombolysis group 14.8% vs 18.7% and in the CABG
group 6.4% vs 12.3%. The 30-day mortality is independent of
gender but depends on age. The chance of 30-day survival
decreases due to diabetes and cancer (OR: 0.885 and 0.60,
respectively), shock (OR: 0.06) and resuscitation (OR: 0.07).
Survival is signiﬁcantly better in case of hypertension (OR: 1.4).
CONCLUSION: Administrative data proved to be appropriate
tools to develop quality indicators, thus its results can be very
useful in improving health care.
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RISK OF MAJOR BLEEDING DURING CONCOMITANT USE OF
ANTIBIOTIC DRUGS AND COUMARIN ANTICOAGULANTS
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OBJECTIVES: To quantify and qualify the risk of major bleed-
ing associated with the use of antibiotic drugs during coumarin
anticoagulant therapy in daily practice. METHODS: Data
for this retrospective cohort study were obtained from the
PHARMO Record Linkage System, including, among others,
linked drug-dispensing records and hospital records for over
three million individuals in deﬁned areas of The Netherlands.
The study cohort included all users of acenocoumarol or phen-
procoumon, aged 40–80 years, for the period 1996–2004. All
patients were followed until the end of their last coumarin dis-
pensing, hospitalisation for bleeding, death, or end of study
period. Number of days on coumarins alone, and number of
days on coumarins in combination with each antibiotic drug
during follow-up, were determined for each patient. We analy-
sed antibiotic drugs for which at least ﬁve patients experienced
a bleeding at least two weeks after anticoagulant therapy com-
menced, and which fell within the risk period of a single anti-
biotic drug. RESULTS: Respectively, 52,102 acenocoumarol
and 7,885 phenprocoumon users met the inclusion criteria for
the study cohort and contributed 139,159 patient-years of
follow-up. During follow-up 838 patients (1.4%) were hospit-
alised for bleeding while taking coumarins. The antibiotic drugs
for which at least ﬁve coumarin users had a bleeding were
doxycycline, amoxicillin, amoxicillin/clavulanic acid, ciprof-
loxacin and cotrimoxazole. Each of these antibiotic drugs was
associated with an increased risk of bleeding. Incidence rates
ranged from 5.2 major bleedings per 10,000 doxycycline-
dispensings to 11.2 major bleedings per 10,000 cotrimoxazole-
dispensings during coumarin use. Corresponding relative
risks for major bleeding, adjusted for gender and age, ranged
from 2.6 (95% CI 1.4–4.8) for doxycycline to 5.3 (95% CI
2.4–11.8) for cotrimoxazole. CONCLUSION: Doxycycline,
amoxicillin, amoxicillin/clavulanic acid, ciproﬂoxacin and cot-
rimoxazole are the main antibiotic drugs associated with an
increased risk of major bleeding during coumarin anticoagulant
therapy in daily practice.
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OBJECTIVES: To characterize epidemiological risk factors,
review clinical outcomes, and overall costs associated with treat-
ing bleeding related to cardiac surgery, and identify areas for
further research. METHODS: A systematic literature search was
performed (1996-March 2007) using terms designed to identify
publications describing epidemiology and associated risk factors,
clinical outcomes, and economic impact of bleeding in cardiac
surgery patients. Studies were identiﬁed through electronic Med-
line® and PubMed® searches. Manual review of bibliographies
within these papers allowed identiﬁcation of additional articles.
RESULTS: A total of 36 (epidemiology: n = 13, clinical out-
comes: n = 14, and economic burden: n = 9) papers [manual
search: n = 12] were included for review. Incidence of bleeding
associated with major cardiac surgical procedures varied widely,
ranging from 0.4%–19.0%, partly attributable to the types of
cardiac operations as well as to differences in the deﬁnition of
bleeding. Pre-operative smaller body mass index, use of anti-
thrombotic drugs, nonelective surgery, increased age, and redo
procedures were associated with bleeding, while embolic events
were found to be major complications. Costs associated with
bleeding requiring transfusion ranged from $397 (blood prod-
ucts only) to $10,225 per patient (all treatment costs), with
hospital LOS as the major cost contributor. Mean cost of open-
heart surgeries [including coronary artery bypass graft (CABG)
and valve replacements] range from $25,057 to $79,795, with
patients undergoing CABG found to have an incremental cost of
$3,866 associated with bleeding. Primary pharmacological treat-
ments for bleeding among cardiac surgery patients included anti-
ﬁbrinolytics and procoagulants. CONCLUSION: Post-operative
bleeding remains a central clinical outcome in cardiac surgery
with signiﬁcant economic impact despite improvements in peri-
operative bleeding management. Sufﬁcient information on recent
cost estimates as well as differences in bleeding costs associated
with various cardiac procedures is lacking. Further research
investigating the economic consequences of bleeding associated
with cardiac surgery is warranted.
CARDIOVASCULAR DISEASE—Cost Studies
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OBJECTIVES: Introduction. The polish system of medication
reimbursement is based on positive list. The government decides
which medication could be reimbursed by adding or removing it
from the list. Additional tool for reimbursement control is the
“medication refund limit” (MRL). The same MRL per DDD is
set for each INN separately or for group of medication, which
have the same indication, form and dose. The payer (National
Fund of Health) partially refunds the cost of medication below
the MRL. The difference between the MRL and price is paid by
patient. In 2006 the government changed the MRL and ofﬁcial
prices for some medication. The aim is to assess the impact of
Abstracts A409
changes in MRL on payer’s and patient’s one year budget on the
example of angiotensin II blockers. METHODS: The three
models were build to assess the changes in payer’s and patient’s
budget/per patient if therapy is conducted using: 1) the only
original medications;2) only generic medications; or 3) if therapy
had been started with original medications and changed to the
generic (after changes on the list). All costs in polish zloty (zł): 1
euro ~ 3.80 zl. RESULTS: In all models (from 1 to 3) the payer’s
payment will decrease from 281 zł to 154 zł pe patient. From the
patient’s perspective the one year payment will rise from 767 zł
to 1048 zł or from 449 zł to 577 zł—depends on medication (in
model 1) and from 281 zł to 409 zł (in model 2), only in model
3 it will decrease from 767 zł to 409 zł. CONCLUSION: The
changes in MRL may lead to reduction of payer’s expenditures
and usually increase the patient’s expenditures. As a result it
could leads to reduction in patient’s access to medications.
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OBJECTIVES:Our aimwas to assess the social insurance costs of
hospital treatments for acute stroke inHungary between 2003 and
2005.We studied howmuch burden stroke patients impose on the
ﬁnancer (National Health Insurer Fund Administration) in acute
and chronic hospital admissions. METHODS: We extracted the
data of ‘new’ stroke patients (ICD-10: I60–64 diagnosis) hospi-
talized in May 2003 from the database of the ﬁnancer. We
analyzed active and chronic hospital treatment costs of these
patients in the period of 12 months before the stroke and in the
following ﬁrst and second 12 months. Data were distributed by
sex and age (age groups: 25–44, 45–64, over 65). We studied
patients hospitalized in May 2003 with the ICD-10: I60–64 main
diagnosis but not treated with the same diagnosis in the previous
24 months.RESULTS: In the ﬁrst 12 months of the active care the
burden of the disease was (male vs. female) 65+: 1018.4 vs. 823.2;
45–64: 1365.6 vs. 1122.0; 25–44: 1480.4 vs. 1224.4 Euro per
patient. In the second 12 months the costs were 202.4 vs. 144.8;
96.8 vs. 130.4; 110.4 vs. 99.2 Euro respectively.CONCLUSION:
Annual stroke costs of the Insurance Fund—based on our inci-
dence data (3535 patients/month)—amounted to 37.6 million
Euros in active and to 4.3 million Euros in chronic hospital care in
the ﬁrst 12 months, which is 1.68% of the total budget. Average
costs of stroke are higher in the case of males as are in the case of
females, 1459.2 vs. 1212.0 Euro in the ﬁrst 24 months. The
signiﬁcant difference results from active hospital treatment costs
(1326.0 vs. 1048.4 Euro), while the discrepancy is smaller in the
chronic hospital care (133.2 vs. 163.6 Euro).
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OBJECTIVES: Estimate the budget impact and the level of thera-
peutic goal attainment among patients with high cardiovascular
risk (HCR) in a population attending primary care setting (PCS)
and Hospital centres (HC) in a Spanish area. METHODS: Obser-
vational multicentre longitudinal study. Patients >55 years old
from seven PCC and two HC were recruited during 2006.
Deﬁnition of HCR as per modiﬁed NCEP-ATP III criteria.
The control cohort: patients without HCR. Main measures:
cardiovascular/general comorbidities, Charlson score (severity
[iCh]), clinical parameters (DP, SP, glucose, cholesterol, HCLc,
LDLc) and total costs variable/semi ﬁxed (visits, tests, drugs,
admissions, derivations, emergencies etc). A logistic regression
and covariance model was developed (ANCOVA-Bonferroni) to
correct the models (comorbidities-cost). SPSS program was used.
Level of signiﬁcance was p < 0.05. RESULTS: In all, 24,410
patient were studied, 15.4% (n = 2.766; IC:14,9–15,9%;
p = 0,000) had HCR, mean age: 68,2  9,5 years, women:
55,2%. HCR was associated with: men (OR = 2,7; IC:2,5–3,0),
dyslipidemia (OR = 1,5; IC:1,4–1,6), hypertension (OR = 1,2;
IC:1,1–1,3), diabetes (OR = 1,1; IC:1,0–1,2) and iCh (OR = 2,1;
IC:1,9–2,2), p < 0,0001. Differences for the group with and
without HCR were: Metabolic control: DP: 77,5  9,5 vs.
74,8  9,7; glucose: 104,0  29,4 vs. 111,3  36,5; Total cho-
lesterol: 211,6  38,7 vs. 192,4  41,5; LDL-cholesterol:
128,7  35,4 vs. 112,5  36,0; p = 0,000. HCR was related to
poly-pharmacy (62,5% vs. 26,1%) and average number of drugs
(6,4  3,5 for the HCR group vs. 4,0  2,9), p < 0,001. Drugs
accounted for 43.4% of total costs. Unitary adjusted cost per
year was 2.445.98€ (IC:2.382,07–2.509,90) for the HCR group
vs. 1.537,33€ (IC:1.505,53–1.569,13), p < 0.001. All compo-
nents of costs showed signiﬁcant differences between groups.
CONCLUSION: Patients with HCR had higher rates of
co-morbidity. Achievement of therapeutic objectives should
improve in patients without hypertension and total cholesterol
but with HCR (glucose, cLDL). Patients with this proﬁle use
more resources (particularly more drugs) and have higher health
care costs. Health professionals should develop common strate-
gies oriented to control main cardiovascular risk factors in
primary care.
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OBJECTIVES: Surgical techniques and immunosuppressive
drugs have been improved over the past decades, while the
method of preserving and transporting organs has not. In the UK
only 22.3% of hearts from all consented heart beating donors
were recovered in June 2005, whilst cold ischeamic time (CIT)
increased by an average of 34 minutes over 8 years. The Organ
Care System (OCS) may alleviate the organ shortage and
improve transplant outcomes by maintaining explanted hearts in
the normal functioning state ex-vivo. A health economic evalu-
ation analysis was undertaken to compute the economic beneﬁt
of improved transportability of explanted hearts from the UK
societal point of view. METHODS: Improved preservation with
OCS plus heart transplantation (IPTx) was compared to medical
management on the transplantation waiting list (MM) and heart
transplantation with conventional cold preservation method
(CPTx). We assumed that IPTx increases heart transplantation
rates by 40% and reduces CIT to <1 hr. UK cost vectors were
derived from the published literature. Twenty year direct medical
costs and QALYs were calculated for each arm. Reducing CIT to
<1 hr may extend the graft half life by 2.2 years (Schnitzler
2006). Discount rates of 6% were used for costs and 1.5% for
QALYs. WTP for a QALY gain was assumed to be 30,000 British
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